Physician profile
Bryan J Krajicek
NPI 1689654303
$469,546.19
in general payments reported to CMS, 2019-2025
42 companies · $183K in 2025
The $183K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $8,692 · 2021: $15K · 2022: $35K · 2023: $55K · 2024: $171K · 2025: $183K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $363K · Consulting Fee: $21K · Food and Beverage: $13K · Travel and Lodging: $12K · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $362,596.00 |
| Consulting Fee | $20,929.50 |
| Food and Beverage | $13,457.09 |
| Travel and Lodging | $12,375.59 |
| Education | $116.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $276,895.41 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $166,352.84 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $7,082.57 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $6,320.68 | 2019-2025 | Trelegy Ellipta, Nucala |
| Amgen INC. | $4,754.87 | 2022-2025 | Tezspire, Tavneos |
| Regeneron Pharmaceuticals, INC. | $4,332.00 | 2024 | Dupixent |
| Grifols USA, LLC | $933.42 | 2019-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $370.02 | 2024-2025 | |
| Verona Pharma, INC. | $266.54 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.70 | 2019-2025 | Ofev, Jascayd |
| Mallinckrodt Hospital Products INC. | $163.48 | 2023-2025 | Acthar |
| Medtronic, INC. | $153.31 | 2025 | Cobalt Dr Mri Surescan, Illumisite |
| Grifols Shared Services North America, INC. | $137.94 | 2023 | Prolastin-C Liquid |
| Insmed, INC. | $129.62 | 2020-2025 | Brinsupri, Arikayce |
| Mylan Specialty L.P. | $124.06 | 2019-2024 | Yupelri |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $119.04 | 2024-2025 | |
| Electromed, INC. | $113.09 | 2019-2025 | Smartvest |
| Genentech USA, INC. | $112.15 | 2019-2023 | Xolair |
| Avadel Cns Pharmaceuticals, LLC | $111.93 | 2024-2025 | Lumryz |
| United Therapeutics Corporation | $79.63 | 2020-2024 | |
| Pulmonx Corporation | $77.46 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Astellas Pharma US INC | $68.42 | 2024 | Cresemba, Ambisome |
| Axsome Therapeutics, INC. | $64.88 | 2024-2025 | Sunosi |
| Abiomed | $63.95 | 2024 | Impella |
| Viatris Specialty LLC | $61.17 | 2025 | Yupelri |
| Vifor Pharma, INC. | $59.26 | 2025 | Zemaira, Veltassa |
| Paratek Pharmaceuticals, INC. | $50.96 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $49.56 | 2025 | Winrevair |
| Caris Mpi, INC. | $38.96 | 2025 | Mi Cancer Seek |
| Actelion Pharmaceuticals US, INC. | $33.03 | 2024-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $32.50 | 2019-2022 | |
| Inspire Medical Systems, INC. | $28.49 | 2025 | Inspire |
| Melinta Therapeutics, LLC | $26.07 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.09 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.53 | 2019 | |
| Baxter Healthcare | $18.49 | 2024 | Hillrom - Life 2000 Ventilation System |
| Sunovion Pharmaceuticals INC. | $18.27 | 2019 | |
| Lilly USA, LLC | $17.88 | 2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $17.63 | 2020 | |
| Circassia INC. | $14.96 | 2020 | |
| Gilead Sciences, INC. | $12.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Krajicek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.